Damora Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -68 | -7 | -10 | -9 |
EBITDA | -27,673 | -200,685 | -3,123 | -3,424 |
EBIT | -27,741 | -200,692 | -3,133 | -3,433 |
Net Income | -27,783 | -200,736 | -3,133 | -3,437 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -20,598 | 566 | -2,616 | -2,237 |
Cash | 532,899 | 257,624 | 7,606 | 10,211 |
Basic Shares | 34,299 | 1,327 | 1,327 | 1,322 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -34 | -181 | -830 | -490 |
EBITDA | -209,755 | -21,217 | -37,519 | -61,134 |
EBIT | -209,789 | -21,398 | -38,349 | -61,624 |
Net Income | -209,839 | -21,439 | -38,349 | -61,624 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -6,726 | -18,623 | -36,911 | -43,128 |
Cash | 257,624 | 14,175 | 21,465 | 32,786 |
Basic Shares | 1,327 | 1,157 | 1,062 | 1,016 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.81 |
2025-12-31 | $2.30 |
2025-09-30 | -$2.36 |
2025-06-30 | -$2.59 |